Alpha-MSH vs DSIP

Melanocortin peptide; activates MC1R (pigmentation/anti-inflammatory), MC3R (energy balance), MC4R (appetite); suppresses NF-κB and pro-inflammatory cytokines

α-Melanocyte-stimulating hormone (α-MSH) is an endogenous 13-amino-acid peptide derived from proteolytic processing of proopiomelanocortin (POMC) that acts through melanocortin receptors (MC1R–MC5R), with biological roles including skin pigmentation, anti-inflammatory signaling, thermoregulation, and energy homeostasis. Its anti-inflammatory actions are mediated principally through MC1R and MC3R activation, leading to inhibition of NF-κB-dependent cytokine production, reduction of pro-inflammatory mediators including IL-1β and TNF-α, and modulation of leukocyte activity in both peripheral and central nervous system compartments. Research published in the Annals of the New York Academy of Sciences has characterized the mechanisms of α-MSH's anti-inflammatory activity in vivo and in vitro, and subsequent work has described new insights into its immunomodulatory functions and therapeutic potential in inflammatory conditions. α-MSH is a research compound with no FDA approval for any indication; no human clinical trials have established safety or efficacy for exogenous α-MSH administration in anti-inflammatory, neuroprotective, or other therapeutic contexts. Alpha-MSH and the melanocortin peptide family α-MSH is the prototype endogenous ligand for the melanocortin receptor family — five receptors (MC1R–MC5R) with distinct tissue distribution and functions. The pharmacological development of synthetic melanocortin analogues has produced several clinically and commercially relevant compounds derived from or inspired by α-MSH: Melanotan I (afamelanotide, MC1R-selective, approved as Scenesse for erythropoietic protoporphyria), Melanotan II (non-selective, superpotent, never approved; extensively used in research), and PT-141/bremelanotide (cyclized Melanotan II analogue, FDA-approved as Vyleesi for female hypoactive sexual desire disorder via MC3R/MC4R). α-MSH itself serves as the structural reference point for this lineage — the pharmacophore binding sequence (His-Phe-Arg-Trp) shared by all active melanocortin analogues is derived from α-MSH residues 6–9. Appetite regulation and obesity research: α-MSH's role in energy homeostasis is mediated through MC4R activation in the hypothalamus, where it acts as an endogenous satiety signal opposing the appetitive effects of AgRP (agouti-related protein). Loss-of-function MC4R mutations are the most common monogenic cause of severe early-onset obesity, establishing the α-MSH/MC4R pathway as a validated target for pharmacological weight management. Setmelanotide (Imcivree), an MC4R agonist, is FDA-approved for obesity caused by MC4R pathway deficiency mutations (POMC deficiency, PCSK1 deficiency, leptin receptor deficiency) — a direct pharmacological descendant of the α-MSH mechanism.

Neuropeptide that modulates sleep architecture by promoting delta-wave sleep patterns. Reduces stress hormones including ACTH and cortisol, and interacts with hypothalamic-pituitary pathways to support recovery and circadian regulation.

DSIP (delta sleep-inducing peptide) is a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) originally isolated from the cerebral venous blood of sleeping rabbits by Schoenenberger and Monnier in 1977, subsequently investigated for roles in sleep regulation, stress response modulation, and neuroendocrine activity across multiple neuropeptide systems. DSIP is proposed to act through modulation of GABAergic and serotonergic neurotransmission and to influence the release of multiple pituitary hormones including LH, GH, and ACTH, though no definitive receptor has been identified and its endogenous physiological role in mammalian sleep architecture remains incompletely understood. Foundational rodent studies demonstrated sleep-promoting effects following central or peripheral administration, and early small human EEG studies reported possible effects on sleep architecture; results have been inconsistent across studies, independent replication has been poor, and sleep-inducing activity in humans has not been established by any controlled clinical trial. DSIP has no FDA approval and no approved therapeutic indication in any jurisdiction; it is a research compound with an unconfirmed receptor target, an unclear mechanism of action, and an inconsistent human evidence base, and commercial availability through research peptide suppliers should not be interpreted as evidence of established clinical utility. DSIP dosage: No human clinical trial has established a reference dosing protocol for synthetic DSIP. Early human studies from the 1970s–80s used intravenous infusion at doses in the nanogram-to-microgram per kilogram range; these studies are dated and not replicated by modern clinical research standards. Research interest in DSIP has explored subcutaneous injection in research contexts. DSIP is a research compound with no approved human dosing guidelines for any indication.